acne
Conditions
Interventions
experimental group:Isotretinoin 10mg qd orally + spironolactone 80mg/day orally for 24 weeks
control group:Isotretinoin 20mg qd orally for 24 weeks
Sponsors
The University of Hong Kong-Shenzhen Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 99 Years
Inclusion criteria
Inclusion criteria: (1) Female, aged >= 20 years; (2) Diagnosed as moderate to severe acne, IGA>=2; (3) No isotretinoin and anti-androgen therapy in the past 6 months, no oral antibiotics in the past 1 month, no new antibiotics, tretinoin, or benzoyl peroxide for topical therapy in the past 2 weeks; (4) Have clear contact information and sign informed consent.
Exclusion criteria
Exclusion criteria: (1) Other systemic diseases accompanied by acne (Addison's disease, Behcet's disease, etc.); (2) With rosacea; (3) Blood pregnancy test for pregnant and lactating women (+) Those who plan to become pregnant within 1 year and who refuse contraception; (4) Allergy to spironolactone isotretinoin; (5) Those who have not been able to use isotretinoin and spironolactone; (6) Orthostatic hypotension and hyperkalemia; (7) Application of potassium-sparing diuretic ACEI angiotensin 2 antagonist NSAID heparin digoxin eplerenone; (8) Inflammatory bowel disease, heart, liver and kidney basic diseases, glutathione/aspartate; aminotransferase/triglycerides/cholesterol exceeding the upper limit of normal 2 times; (9) People who are currently suffering from depression or have a history and family history of depression; (10) Participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of illness; | — |
Countries
China
Contacts
Public ContactZhang Zhenying
The University of Hong Kong-Shenzhen Hospital
Outcome results
None listed